OWL | Ophthalmic Innovation | Advancing Diversity in Leadership

OWL Membership

Learn More

Partner With Us

Learn More

Upcoming Events

Learn More
“Let’s Keep in Touch”

Sign up for access to exclusive content, events, materials and updates from OWL.

Join OWL

Rarely will you find a value as great as an OWL membership! By becoming a member you establish yourself as committed to "Advancing Diversity in Leadership" and in standing as a leader for today's world. You'll also be affiliated with the best and brightest in Ophthalmology. Take a look here at some of our Champion members!



Get Involved

Developing leaders is OWL's mission and our specialty!  Get terrific experience and benefit from the best-of-the-best networking in Ophthalmology when you get involved in OWL:

  • Attend an Event
  • Submit an article for our magazine
  • Step into leadership – join an OWL Committee
  • Offer to help with a "one-time" job at one of OWL's fabulous events
  • Connect with us on social media to stay up-to-date with OWL

Support OWL

OWL is a 501(c)3 organization, meaning any financial contribution is 100% tax-deductible.  OWL focuses the investment of members’ dues on programs and events that will benefit members (our admin costs are low compared to other nonprofits).

Your company can align with OWL's mission by having a presence at our events and benefit from exposure on our social mediachannels and in our member communications.  Organizations and companies that want to be involved at the highest level can enroll their associates as virtual members, receive educational programs and get sponsorship exposure by becoming an OWL Partner.


Owl Awards

The OWL Awards are given annually at OWL's Signature Event during AAO.  The finalists are distinguished and respected - always an impressive group!

Nominations for the OWL Awards open in the Summer.  A Nominations Committee selects the finalists and then OWL members cast their votes in the Fall.

Contact Us for information on nominating a colleague as a ‘Rising Star’, ‘Catalyst’ or ‘Visionary’ in Ophthalmology.


Upcoming Programs

OWL Texas Chapter 'Friendsgiving'
11.30.22 | 5:00 PM CST
Atico, 2315 N Main St, Forth Worth, TX 76164
OWL SoCal Chapter Holiday Networking Connect
12.6.22 | 5:30 PM PST
STAAR Surgical, 25691 Atlantic Ocean Dr. Building B3, Lake Forest, CA 92630
OWL & WIO Reception at Hawaiian Eye
1.16.23 | 4 PM HST
Stevenson's Sushi & Spirits - Grand Hyatt Kauai Resort & Spa, 1571 Poipu Road Koloa, Hawaii 96756

Featured Champion Members

Dr. Christina Grek

Senior Director Of Research And Development

Dr. Grek is an accomplished biomedical scientist and industry R&D leader who has successfully led multiple therapeutics from the early product concept through to clinical proof of concept and clinical development in preparation for commercial product launch. With foundations in both industry and academia, her previous expertise includes drug discovery research at Scios Inc., a biopharmaceutical company developing novel drugs for the potential treatment of cardiovascular and inflammatory diseases, acquired by Johnson and Johnson, as well as working on the drug discovery team at SUGEN, a pioneering drug discovery company focused on the development of small-molecule protein kinase inhibitors as cancer therapeutics that was acquired by Pfizer. She is also an adjunct professor at the Medical University of South Carolina in the Department of Cell and Molecular Pharmacology and Experimental Therapeutics.

Dr. Grek has a PhD in Biomedical Sciences from the Medical University of South Carolina, Charleston, SC, and completed her undergraduate studies in biology and chemistry at Queen’s University in Kingston, Ontario, Canada. Dr. Grek joined Xequel Bio in 2013 to lead the development of Xequel’s translational portfolio. These efforts led to several breakthroughs revealing the therapeutic potential in targeting connexin signaling in a number of therapeutic indications with unmet medical needs including ophthalmic disorders, thermal burns, cancers, radiation injury, lung disease, and organ preservation. She currently leads Xequel’s Research and Development team, where she also plays a key role in guiding the design and implementation of the early and late-stage clinical programs in Xequel’s pipeline. She has published book chapters, review articles, and first authored publications in peer reviewed journals as well as holds several patents.

More OWL Champions
Greg Kunst

President and Chief Executive Officer,
Aurion Biotech

Greg Kunst joins Aurion Biotech with deep and varied experience in ophthalmic medical devices, drug delivery systems, diagnostics, biotechnology, and pharmaceutical products. His expertise spans global corporate development, strategy, health policy, marketing, commercialization, business development, market access and medical affairs.

Before Aurion Biotech, Greg spent 6 years at Glaukos Corporation (NYSE: GKOS) in numerous roles of increasing responsibility, most recently as vice president of global marketing, where he led the global marketing, market access, reimbursement, health economics and outcomes research, government affairs, and business development teams. Before Glaukos, Greg worked at Alcon, a Novartis company, as global franchise director over the Alcon glaucoma surgery and retina pharmaceutical businesses. Before joining Alcon, Greg worked at Kinetic Concepts, Inc. (Acelity Inc.) as the global head of market access. Greg is a member of the steering committee for the Gavin Herbert Eye Institute at the University of California, Irvine.

Greg received an MBA from Vanderbilt University and a BS in Economics from Brigham Young University.

More OWL Champions